RNA Avidity Biosciences: Rasio rega marang prakiraan pendapatan
Avidity Biosciences (RNA) is expanding its RNA therapy trial program to combat muscular dystrophies. Innovations in drug delivery and the probability of deals with industry behemoths are driving growth. However, financial stability remains fragile due to dependence on regulatory verdicts. The forward P/S based on forecasts demonstrates the impact of interest rates on share prices, where the value 585.30 shows the current magnitude of this indicator.
RNA (Avidity Corp): rincian analitis lan laporan miturut indikator
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Avidity Biosciences|RNA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Avidity Biosciences|RNA - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Avidity Corp|RNA - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Avidity Biosciences|Likuiditas cepet aviditybiosciences.com
- rincian asil keuangan lan kelipatan valuasi:
RNA - Asil keuangan resik|Bathi sing dikarepake Avidity Biosciences|RNA - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Avidity|RNA - Rasio P/E diaturake wutah|Pangali EV/EBITDA Avidity Corp|RNA - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Avidity Biosciences|RNA - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan aviditybiosciences.com|RNA - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Avidity Biosciences
- data dodolan lan asil:
Pambiji fundamental perusahaan:Avidity Biosciences, Inc. RNA
To find a balance between asset quality and cost, an investor analyzes market capitalization dynamics relative to projected sales volumes, which allows for an assessment of the premium for future growth. In the case of Avidity Biosciences (RNA), which has no current sales, the expected market cap-to-revenue ratio reflects the speculative value of the RNA drug platform and market optimism ahead of the publication of final clinical trial data.
Pesaing Avidity Biosciences (RNA)
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Qiagen NV (QGEN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Repligen Inc. RGEN|CRSP: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan genedx.com|RARE (Ultragenyx) - Multiplikator Forward P/S|Beam Therapeutics Inc (BEAM) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S SRPT|TWST - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan 10x Genomics, Inc. TXG|NTLA: Kapitalisasi marang prakiraan pendapatan|Stoke Therapeutics, Inc. - Multiplikator Forward P/S|BioLife Solutions Inc (BLFS) - Multiplikator forward rega marang pendapatan|WVE: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Maze Therapeutics Corp (MAZE)|Rasio rega marang prakiraan pendapatan Sionna Therapeutics Inc|primemedicine.com (PRME) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Taysha Gene Therapies, Inc. (TSHA)|QURE (uniQure NV) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan MeiraGTx PLC MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc. - Multiplikator Forward P/S|OCGN - Multiplikator Forward P/S|PACB: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan BNTC|Rasio rega marang prakiraan pendapatan Design Pharma|Kapitalisasi marang prakiraan pendapatan RCKT (Rocket Corp)|Multiplikator Forward P/S FDMT|Multiplikator Forward P/S lexeotx.com (LXEO)|Multiplikator Forward P/S KRRO (Korro Bio)|Multiplikator Forward P/S Editas Medicine Inc EDIT|SLN: Multiplikator forward rega marang pendapatan|PRQR: Rasio rega marang prakiraan pendapatan|CDXS: Multiplikator Forward P/S|SGMO - Rasio kapitalisasi marang dodolan sing dikarepake|NAUT (Nautilus Biotechnology, Inc.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan MGX (Metagenomi Inc.)|Multiplikator Forward P/S DTIL|Rasio kapitalisasi marang dodolan sing dikarepake generationbio.com|Boundless Bio, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake XCUR (Exicure Inc.)|IMNN: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals|MBIO (mustangbio.com) - Multiplikator forward rega marang pendapatan|TransCode Therapeutics, Inc. - Rega forward marang dodolan|BNGO (Bionano Genomics Inc.) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan APDN|Multiplikator Forward P/S BLUE|Rasio kapitalisasi marang dodolan sing dikarepake immunoprecise.com|Rasio rega marang prakiraan pendapatan Omega OMGA|Singular Genomics Corp (OMIC) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RGLS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake syros.com SYRS|TBIO: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan TRACON Pharmaceuticals Inc.|UBX (Unity Bio) - Multiplikator Forward P/S
